Dantrolene
- Atc Codes:M03CA01
- CAS Codes:24868-20-0#14663-23-1#7261-97-4
- PHARMGKB ID:24868-20-0#14663-23-1#7261-97-4
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Toxicological Effects
- Genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Dantrolen; Belgium: Dantrium; Czech Republic: Dantrolen; France: Dantrium; Germany: Dantamacrin, Dantrium, Dantrolen; Greece: Dantrium, Dantrolen; Hungary: Dantrolen; Ireland: Dantrium; Italy: Dantrium; Luxembourg: Dantrium; Malta: Dantrium; Netherlands: Dantrium; Slovakia: Dantrolen; UK: Dantrium.
North America
Canada: Dantrium; USA: Dantrium, Dantrolene.
Latin America
Argentina: Dantrolen, Dantrolene; Brazil: Dantrolen.
Asia
Japan: Dantrium.
Drug combinations
Chemistry
Dantrolene Sodium: C~14~H~9~N~4~NaO~5~ 3½H~2~O. Mw: 399.29. (1) 2,4-Imidazolidinedione, 1-[[[5-(4-nitrophenyl)-2-furanyl]methylene]amino]-, sodium salt, hydrate (2:7); (2) 1-[[5-(p-Nitrophenyl)furfurylidene]amino]hydantoin sodium salt hydrate. CAS-24868-20-0; CAS-14663-23-1 (anhydrous); CAS-7261-97-4 (dantrolene)(1968).
Pharmacologic Category
Direct-acting Skeletal Muscle Relaxants. (ATC-Code: M03CA01).
Mechanism of action
Acts directly on skeletal muscle by interfering with release of calcium ion from sarcoplasmic reticulum. Prevents or reduces increase in myoplasmic calcium ion concentration, which activates the acute catabolic processes associated with malignant hyperthermia.
Therapeutic use
Management of spasticity associated with spinal cord injury, stroke, cerebral palsy, or multiple sclerosis. Management of malignant hyperthermia crisis.
Pregnancy and lactiation implications
Should not be used in women who are or may become pregnant unless possible benefits outweigh potential risks to the fetus. Should not be administered to nursing women.
Unlabeled use
Neuroleptic malignant syndrome.
Contraindications
Contraindicated in upper motor neuron disorders and active hepatic disease (hepatitis and cirrhosis). Should not be used where spasticity is used to maintain posture or balance.
Warnings and precautions
Avoid extravasation (tissue irritant). May cause severe hepatotoxicity (risk increased in females, in patients older than 35 years of age, and in those concomitantly receiving other drugs (especially estrogens)). Caution in history of previous liver disease or dysfunction. Caution in impaired cardiac function (due to myocardial disease) or impaired pulmonary function (particularly with obstructive pulmonary disease).